This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Phillips, S. A. Articles by Yen, P. M. Search for Related Content PubMed PubMed Citation Articles by Phillips, S. A. Articles by Yen, P. M.

Extreme Thyroid Hormone Resistance in a Patient with a Novel Truncated TR Mutant

Diabetes and Molecular Regulation and Neuroendocrinology Sections, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892; University of Maryland School of Medicine (J.L.), Baltimore, Maryland 21201; Portland Veterans Affairs Medical Center, Department of Psychiatry, Oregon Health Sciences University (P.H.), Portland, Oregon 97201; and Department of Medicine, Centre Hospitalier, Universite de Nice (F.B.-D.), Nice, France

Address all correspondence and requests for reprints to: Paul M. Yen, M.D., Molecular Regulation and Neuroendocrinology Section, Clinical Endocrinology Branch, National Institutes of Health, Building 10, Room 8D12, Bethesda, Maryland 20892. E-mail: pauly{at}intra.niddk.nih.gov

Abstract

Resistance to thyroid hormone (RTH) is a syndrome in which patients have elevated thyroid hormone (TH) levels and decreased sensitivity to its action. We describe a child with extreme RTH and a severe phenotype. A 22-month-old female presented to the NIH with goiter, growth retardation, short stature, and deafness. Additionally, the patient had hypotonia, mental retardation, visual impairment, and a history of seizures. Brain magnetic resonance imaging showed evidence of demyelination and bilateral ventricular enlargement. The patient had markedly elevated free T₃ and free T₄ levels of more than 2000 pg/dl (normal, 230–420 pg/dl) and more than 64 pmol/liter (normal, 10.3–20.6 pmol/liter), respectively, and TSH of 6.88 mU/liter (normal, 0.6–6.3 mU/liter). These are the highest TH levels reported for a heterozygous RTH patient. A T₃ stimulation test confirmed the diagnosis of RTH in the pituitary and peripheral tissues. Molecular analyses of the patient’s genomic DNA by PCR identified a single base deletion in exon 10 of her TRß gene that resulted in a frameshift and early stop codon. This, in turn, encoded a truncated receptor that lacked the last 20 amino acids. Cotransfection studies showed that the mutant TR was transcriptionally inactive even in the presence of 10^-6 M T₃ and had strong dominant negative activity over the wild-type receptor. It is likely that the severely defective TRß mutant contributed to the extreme RTH phenotype and resistance in our patient.

This article has been cited by other articles:

				J. Lado-Abeal, A. M. Dumitrescu, X.-H. Liao, R. N. Cohen, J. Pohlenz, R. E. Weiss, M.-C. Lebrethon, A. Verloes, and S. Refetoff A De Novo Mutation in an Already Mutant Nucleotide of the Thyroid Hormone Receptor {beta} Gene Perpetuates Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1760 - 1767. [Abstract] [Full Text] [PDF]

				L. Ng, R. J. Goodyear, C. A. Woods, M. J. Schneider, E. Diamond, G. P. Richardson, M. W. Kelley, D. L. St. Germain, V. A. Galton, and D. Forrest Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase PNAS, March 9, 2004; 101(10): 3474 - 3479. [Abstract] [Full Text] [PDF]